Health status and health care costs for publicly funded patients with schizophrenia started on clozapine

Psychiatric Services

Volumn 49, Issue 12, 1998, Pages 1590-1593

  Blieden, Nancy ^a   Flinders, Susan ^a   Hawkins, Kevin ^a,b   Reid, Michele ^a,c   Alphs, Larry D ^a,d   Arfken, Cynthia L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

^c Detroit Wayne Co Comm Mental H

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA;

EID: 0031700976     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.49.12.1590     Document Type: Article

References (18)

1. Michigan Critical Health Indicators. Lansing, Michigan Department of Community Health, 1996
2. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. American Journal of Psychiatry 150:1448-1465, 1993
3. Rupp A, Keith SJ: The costs of schizophrenia: assessing the burden. Psychiatric Clinics of North America 16:413-422, 1993
4. Meltzer HY, Cola PA: The pharmacoeconomics of clozapine: a review. Journal of Clinical Psychiatry 55(suppl B):161-165, 1994
5. Fitton A, Benfield P: Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics 4:131-156, 1993
6. Meltzer HY, Cola PA, Way L, et al: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry 150:1630-1638, 1993
7. Revicki DA, Luce BR, Weschler JM, et al: Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry 41: 850-854, 1990
8. Hargreaves WA, Shumway M: Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry 57(suppl 9):66-76, 1996
9. Frankenburg FR, Zanarini MC, Cole JO, et al: Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Annals of Clinical Psychiatry 4: 247-250, 1992
10. Rosenheck R, Cramer J, Weichun X, et al: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337:809-815, 1997
11. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychological Reports 10:799-812, 1962
12. Alphs LD, Summerfelt BS, Lann HS, et al: The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacology Bulletin 21:159-163, 1989
13. Hamilton M: Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6:278-296, 1967
14. Heinrichs DW, Hanlon ET, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenia deficit syndrome. Schizophrenia Bulletin 10:388-398, 1984
15. O'Brien PC: Procedures for comparing samples with multiple endpoints. Biometrics 40:1079-1087, 1984
16. Kane JM, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
17. Reid WH, Mason M, Toprac M: Savings in hospital bed-days related to treatment with clozapine. Hospital and Community Psychiatry 45:261-264, 1994
18. Carpenter WT, Conley RR, Buchanan RW, et al: Patient response and resource management: another view of clozapine treatment of schizophrenia. American Journal of Psychiatry 152:827-832, 1995